PubRank

T Turpeenniemi-Hujanen

Author PubWeight™ 46.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice. Mol Cell Biol 1985 1.48
2 Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res 2000 1.45
3 Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003 1.45
4 Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001 1.33
5 Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998 1.32
6 Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. Int J Cancer 1982 1.31
7 Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 1985 1.14
8 Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996 1.13
9 Molecular cloning of chick lysyl hydroxylase. Little homology in primary structure to the two types of subunit of prolyl 4-hydroxylase. J Biol Chem 1991 1.12
10 Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 2006 1.09
11 Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem 1986 1.09
12 Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998 1.08
13 Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 2000 1.02
14 Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001 1.02
15 Tumor-promoting phorbol esters and cell proliferation stimulate secretion of basement membrane (type IV) collagen-degrading metalloproteinase by human fibroblasts. J Biol Chem 1985 1.02
16 Serum concentrations of collagen degrading enzymes and their inhibitors after downhill running. Scand J Med Sci Sports 2001 1.01
17 Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett 1988 0.98
18 Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005 0.98
19 Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001 0.96
20 Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer 1990 0.95
21 MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 1999 0.91
22 Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999 0.90
23 Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 2007 0.89
24 Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). Gynecol Oncol 1997 0.89
25 Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 1994 0.89
26 Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metastasis 1997 0.89
27 p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 1995 0.89
28 Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma? J Pathol 1999 0.88
29 Protein synthesis but not DNA synthesis is required for tumor cell invasion in vitro. Invasion Metastasis 1984 0.88
30 Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011 0.87
31 Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol 2004 0.86
32 High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. Cancer Biomark 2007 0.85
33 Cancer cells, components of basement membranes, and proteolytic enzymes. Int Rev Exp Pathol 1985 0.85
34 Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology 1994 0.84
35 Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett 2005 0.84
36 MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol 2006 0.84
37 The human embryo produces basement membrane collagen (type IV collagen)-degrading protease activity. Hum Reprod 1989 0.83
38 Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 2006 0.83
39 Regulation of 72-kd type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-releasing hormone agonist in human granulosa-lutein cells. Fertil Steril 1995 0.82
40 Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status. Exp Cell Res 2012 0.82
41 Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 2009 0.81
42 p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993 0.79
43 Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 2000 0.77
44 Matrix metalloproteinase 9 in the uterine cervix during tumor progression. Int J Gynaecol Obstet 2005 0.77
45 Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 2000 0.77
46 Purification and characterization of a connective-tissue-degrading metalloproteinase from the cytosol of metastatic melanoma cells. Biochem J 1987 0.77
47 MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res 2001 0.77
48 Expression of oncogenes in cancer metastases. Prog Clin Biol Res 1986 0.76
49 Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast. Tumour Biol 2009 0.75
50 Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005 0.75
51 Matrix metalloproteinase 9 and relapse in patients with early stage squamous cervical carcinoma. Int J Gynaecol Obstet 2005 0.75
52 Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. Ann Oncol 2009 0.75
53 Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro. Int J Cancer 1991 0.75
54 Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro. Biochim Biophys Acta 1984 0.75
55 MACOP-B regimen in non-Hodgkin's lymphoma. Acta Oncol 1992 0.75
56 Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro. Leuk Lymphoma 2001 0.75